Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1988 1
1990 1
1991 1
1993 1
1996 1
1998 2
1999 2
2001 1
2002 2
2003 1
2004 1
2008 2
2009 2
2010 1
2011 2
2012 2
2013 2
2015 1
2017 3
2018 2
2019 5
2020 3
2021 2
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hbsag and heart (181 results)?
Schisandrin C enhances cGAS-STING pathway activation and inhibits HBV replication.
Zhao J, Xu G, Hou X, Mu W, Yang H, Shi W, Wen J, Liu T, Wu Z, Bai J, Zhang P, Wang Z, Xiao X, Zou W, Bai Z, Zhan X. Zhao J, et al. J Ethnopharmacol. 2023 Jul 15;311:116427. doi: 10.1016/j.jep.2023.116427. Epub 2023 Mar 30. J Ethnopharmacol. 2023. PMID: 37001770
Baill. is a long-term used traditional Chinese medicine with the functions of tonifying the kidney and calming the heart, tonifying qi and engendering fluid. It can be used to treat insomnia and dreaminess, spermatorrhea, coughs, as well as liver and kidney deficiency of Y …
Baill. is a long-term used traditional Chinese medicine with the functions of tonifying the kidney and calming the heart, tonifying q …
Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection.
Downs LO, Smith DA, Lumley SF, Patel M, McNaughton AL, Mokaya J, Ansari MA, Salih H, Várnai KA, Freeman O, Cripps S, Phillips J, Collier J, Woods K, Channon K, Davies J, Barnes E, Jeffery K, Matthews PC. Downs LO, et al. mBio. 2019 Jun 25;10(3):e00699-19. doi: 10.1128/mBio.00699-19. mBio. 2019. PMID: 31239374 Free PMC article.
HBsAg and HBeAg have gained traction as biomarkers of control and clearance during chronic hepatitis B virus infection (CHB). ...Those who cleared HBsAg were significantly older and less likely to be on NA therapy than nonclearers (P = 0.003 and P = 0.001, respectively). C …
HBsAg and HBeAg have gained traction as biomarkers of control and clearance during chronic hepatitis B virus infection (CHB). ...Thos …
Comparing the efficacy and safety of tenofovir and adefovir or combined drug treatment for the treatment of chronic hepatitis B infection: a systematic review and meta-analysis.
Bi Z, Wang L, Hou H, Lu M, Wang W, Li Z, Liu C. Bi Z, et al. Ann Transl Med. 2022 Sep;10(18):1016. doi: 10.21037/atm-22-3747. Ann Transl Med. 2022. PMID: 36267714 Free PMC article.
CONCLUSIONS: Results showed that TDF was superior to ADV in the parameters of ALT, hepatitis B virus (HBV)-DNA reduction, HBeAg-negative conversion rate, safety, and total bilirubin levels in patients with CHB. ...
CONCLUSIONS: Results showed that TDF was superior to ADV in the parameters of ALT, hepatitis B virus (HBV)-DNA reduction, HBeAg-negat …
Chronic hepatitis virus infection in children.
Chang MH. Chang MH. J Gastroenterol Hepatol. 1998 May;13(5):541-8. doi: 10.1111/j.1440-1746.1998.tb00685.x. J Gastroenterol Hepatol. 1998. PMID: 9641657 Review.
During the natural course of chronic HBV infection, spontaneous HBeAg/anti-HBe seroconversion occurs very rarely (2% annually) before 3 years of age. After 3 years of age, the HBeAg seroconversion rate increases gradually to 5% per year. Those with mothers who are h …
During the natural course of chronic HBV infection, spontaneous HBeAg/anti-HBe seroconversion occurs very rarely (2% annually) before …
Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials.
Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD. Wong WWL, et al. Syst Rev. 2019 Aug 19;8(1):207. doi: 10.1186/s13643-019-1126-1. Syst Rev. 2019. PMID: 31426837 Free PMC article.
The endpoints were virologic response (VR), normalization of alanine aminotransferase (ALT norm), HBeAg loss, HBeAg seroconversion, and HBsAg loss for the HBeAg-positive population; and VR and ALT norm for the HBeAg-negative population. ...RESULTS: For …
The endpoints were virologic response (VR), normalization of alanine aminotransferase (ALT norm), HBeAg loss, HBeAg seroconver …
Immune response pattern varies with the natural history of chronic hepatitis B.
Wang WT, Zhao XQ, Li GP, Chen YZ, Wang L, Han MF, Li WN, Chen T, Chen G, Xu D, Ning Q, Zhao XP. Wang WT, et al. World J Gastroenterol. 2019 Apr 28;25(16):1950-1963. doi: 10.3748/wjg.v25.i16.1950. World J Gastroenterol. 2019. PMID: 31086463 Free PMC article.
BACKGROUND: Chronic hepatitis B is a highly heterogeneous disease that can be divided into four phases: Immune tolerant (IT), immune active (IA), inactive carrier (IC) and hepatitis B envelope antigen (HBeAg)-negative hepatitis (ENEG). AIM: To investigate the immune status …
BACKGROUND: Chronic hepatitis B is a highly heterogeneous disease that can be divided into four phases: Immune tolerant (IT), immune active …
Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.
Jang H, Yoon JS, Park SY, Lee HA, Jang MJ, Kim SU, Sinn DH, Seo YS, Kim HY, Kim SE, Jun DW, Yoon EL, Sohn JH, Ahn SB, Shim JJ, Jeong SW, Cho YK, Kim HS, Nam JY, Lee YB, Kim YJ, Yoon JH, Zoulim F, Lampertico P, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Papatheodoridis GV, Lee JH. Jang H, et al. Clin Gastroenterol Hepatol. 2022 Jun;20(6):1343-1353.e16. doi: 10.1016/j.cgh.2021.09.001. Epub 2021 Sep 6. Clin Gastroenterol Hepatol. 2022. PMID: 34500103
We investigated the impact of HBeAg status at the onset of antiviral treatment on the risk of HCC. ...In the Caucasian cohort (n = 719; mean age, 51.8 years; HBeAg-positive, 20.3%; cirrhosis, 34.8%), HBeAg-positivity was not associated with the risk of HCC ei …
We investigated the impact of HBeAg status at the onset of antiviral treatment on the risk of HCC. ...In the Caucasian cohort (n = 71 …
Risk Factors of Chronic Kidney Disease in Chronic Hepatitis B: A Hospital-based Case-control Study from China.
Liu Y, Wang X, Xu F, Li D, Yang H, Sun N, Fan YC, Yang X. Liu Y, et al. J Clin Transl Hepatol. 2022 Apr 28;10(2):238-246. doi: 10.14218/JCTH.2021.00082. Epub 2021 Jul 23. J Clin Transl Hepatol. 2022. PMID: 35528983 Free PMC article.
Duration of HBV infection, Log(10) HBsAg, HBeAg-positive status and dyslipidemia remained the risk factors for CKD after adjusting for diabetes mellitus, hypertension, and coronary heart disease. CONCLUSIONS: Duration of HBV infection, Log(10) HBsAg, HBeAg-po …
Duration of HBV infection, Log(10) HBsAg, HBeAg-positive status and dyslipidemia remained the risk factors for CKD after adjusting fo …
Adefovir treatment for chronic hepatitis B in heart transplant recipients.
Durante-Mangoni E, Iossa D, Pinto D, Molaro R, Agrusta F, Amarelli C, Ragone E, Grimaldi M, Maiello C, Utili R. Durante-Mangoni E, et al. Clin Transplant. 2013 May-Jun;27(3):E282-8. doi: 10.1111/ctr.12109. Epub 2013 Mar 21. Clin Transplant. 2013. PMID: 23517019
Of eight patients, six had fibrosis score 2 and negative HBeAg and seven had hepatitis B virus (HBV) genotype D. Upon ADV start, median HBV-DNA was 5.8 logs IU/mL and alanine aminotransferase (ALT) levels were mostly normal. ...Our data suggest that ADV may be a safe and e …
Of eight patients, six had fibrosis score 2 and negative HBeAg and seven had hepatitis B virus (HBV) genotype D. Upon ADV start, medi …
41 results